HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Heart 2005;91:1265-1270; doi:10.1136/hrt.2004.048314
Copyright © 2005 BMJ Publishing Group Ltd & British Cardiovascular Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cormican, L J
Right arrow Articles by Williams, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cormican, L J
Right arrow Articles by Williams, A

REVIEW

Sleep disordered breathing and its treatment in congestive heart failure

L J Cormican, A Williams

Sleep Disorders Centre, Guy’s and St Thomas’ NHS Trust, London, UK

Correspondence to:
Correspondence to:
Dr Liam Cormican
Sleep Disorders Centre, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, UK; cormitron{at}yahoo.com


ABSTRACT
Sleep disordered breathing (SDB) is a common problem with adverse cardiorespiratory, endocrinological, and endothelial effects. Recent studies demonstrate an even higher prevalence of SDB in congestive heart failure (CHF) than in a randomly selected population, with up to 40% and 11% having Cheyne Stokes respiration–central sleep apnoea and obstructive sleep apnoea–hypopnoea syndromes, respectively. Randomised controlled trials of nocturnal respiratory support for SDB associated with CHF for up to three months demonstrate significant benefits in terms of improvements in left ventricular ejection fraction, markers of sympathetic system activity, and quality of life. Further randomised controlled trials of larger scale and longer duration are required to establish the role and benefit of this intervention for the treatment of this debilitating condition. The evidence for the higher prevalence of SDB in CHF, its pathogenesis, its pathophysiological consequences, and the emerging benefits of respiratory support are reviewed.


Abbreviations: CANPAP, Canadian continuous positive airway pressure; CHF, congestive heart failure; CPAP, continuous positive airway pressure; CSA, central sleep apnoea; CSR, Cheyne-Stokes respiration; NYHA, New York Heart Association; OSAHS, obstructive sleep apnoea hypopnoea syndrome; PCO2, partial pressure of carbon dioxide; SDB, sleep disordered breathing

Keywords: sleep disordered breathing; heart failure




This article has been cited by other articles:


Home page
HeartHome page
C. C Lang and D. M Mancini
Non-cardiac comorbidities in chronic heart failure
Heart, June 1, 2007; 93(6): 665 - 671.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & British Cardiovascular Society